Jardiance vs Tresiba: Side-Effect Profile Head-to-Head

Why These Two Drugs Get Compared

Jardiance and Tresiba occupy different rungs on most type 2 diabetes treatment algorithms, yet prescribers frequently weigh one against the other when oral therapy alone stops controlling HbA1c. The comparison is common because both drugs can be added to metformin, both are taken once daily, and both appear in the ADA/EASD consensus recommendations for second-line intensification 1.

The choice often hinges on side-effect tolerance rather than raw glucose-lowering power. A patient with established cardiovascular disease may lean toward Jardiance for its proven mortality benefit. A patient with an HbA1c of 10.5% who needs rapid correction might benefit more from the potent glucose-lowering effect of a basal insulin like Tresiba. Cross-trial comparisons are imperfect. EMPA-REG OUTCOME enrolled patients with established atherosclerotic CVD, while DEVOTE enrolled a broader population with cardiovascular risk factors 2 3. Baseline characteristics, background medications, and endpoint definitions differed. Every comparison in this article should be read with that caveat in mind.

Hypoglycemia: The Defining Difference

Hypoglycemia is the single largest side-effect gap between these drugs. Tresiba is insulin. It lowers blood glucose directly, and giving too much or eating too little triggers hypoglycemia. Jardiance works by blocking glucose reabsorption in the kidney, an insulin-independent mechanism that almost never causes low blood sugar when used without a sulfonylurea or insulin 4.

In DEVOTE (N=7,637), insulin degludec produced a 40% lower rate of severe hypoglycemia compared with insulin glargine U100 (4.9% vs 6.6%, HR 0.60, P<0.001 for superiority) 3. Nocturnal severe hypoglycemia was 53% lower. Those numbers are favorable for a basal insulin, but the absolute rates still dwarf anything seen with SGLT2 inhibitor monotherapy. In EMPA-REG OUTCOME, hypoglycemic events requiring assistance occurred at similar low rates in the empagliflozin and placebo arms 2.

The practical implication: patients on Tresiba need glucose monitoring, dose titration, and education on hypoglycemia management. Patients on Jardiance monotherapy generally do not. Clinicians who are adding Jardiance to an existing insulin regimen should anticipate the need to reduce the insulin dose by 10-20% to avoid stacking hypoglycemia risk.

Genital and Urinary Tract Infections

Jardiance's mechanism, which causes glucosuria (glucose in the urine), creates a warm, sugar-rich environment in the urogenital tract. This raises the rate of genital mycotic infections substantially. In the pooled phase III empagliflozin data, genital infections occurred in approximately 5-6% of women and 1-3% of men on empagliflozin 25 mg, compared with roughly 1.5% and 0.4% on placebo 5. Most cases were mild vulvovaginal candidiasis or balanitis treatable with a single course of topical antifungals.

Urinary tract infections showed a smaller signal. Women taking empagliflozin had modestly higher UTI rates than placebo (approximately 9% vs 8%), a difference that was not statistically significant in most individual trials but consistently trended upward across the class 5.

Tresiba carries neither risk. Insulin does not cause glucosuria and has no known association with genital or urinary infections. For patients with recurrent candidiasis or a history of complicated UTIs, this difference may tip the scale toward basal insulin intensification.

Cardiovascular Outcomes

This is where Jardiance holds its strongest card. EMPA-REG OUTCOME randomized 7,020 patients with type 2 diabetes and established cardiovascular disease to empagliflozin (10 mg or 25 mg) or placebo, added to standard care. Over a median follow-up of 3.1 years, empagliflozin reduced cardiovascular death by 38% (HR 0.62 to 95% CI 0.49-0.77, P<0.001) and hospitalization for heart failure by 35% 2. All-cause mortality dropped by 32%.

DEVOTE was designed differently. Its primary objective was to prove that insulin degludec did not increase cardiovascular risk compared with insulin glargine U100. It succeeded: the hazard ratio for major adverse cardiovascular events (MACE) was 0.91 (95% CI 0.78-1.06), confirming non-inferiority 3. Tresiba does not worsen cardiovascular outcomes, but it has not demonstrated the active benefit that Jardiance has.

The 2022 ADA Standards of Care recommend SGLT2 inhibitors (including empagliflozin) as preferred add-on therapy for patients with established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, regardless of HbA1c level 6. That guideline recommendation rests heavily on outcomes like those from EMPA-REG OUTCOME.

Dr. Silvio Inzucchi, lead investigator of EMPA-REG OUTCOME, noted: "The cardiovascular mortality benefit emerged within the first few months of treatment, suggesting a hemodynamic rather than anti-atherosclerotic mechanism" 2.

Weight Effects

Body weight changes are clinically meaningful for patients with type 2 diabetes, most of whom also carry excess adiposity.

Jardiance produces consistent weight loss. In EMPA-REG OUTCOME, patients on empagliflozin 25 mg lost approximately 2.0 kg more than placebo at 28 weeks, an effect that persisted through the trial 2. The mechanism is caloric: glucosuria wastes roughly 60-80 g of glucose (240-320 kcal) per day. Some of the early weight loss reflects volume depletion from the osmotic diuretic effect, but body composition studies using DXA have confirmed true fat mass reduction with SGLT2 inhibitors 7.

Tresiba causes weight gain. In the BEGIN clinical trial program, patients titrated to target on insulin degludec gained 1-3 kg over 26-52 weeks, consistent with the anabolic properties of exogenous insulin 8. Insulin promotes glucose uptake into cells and suppresses lipolysis. This is pharmacologically expected.

The net weight difference between the two approaches can reach 3-5 kg over a year. For patients already struggling with weight management, this gap matters. It also influences adherence: some patients discontinue insulin specifically because of weight gain.

Volume Depletion and Blood Pressure

Jardiance causes an osmotic diuresis. By excreting glucose through the kidneys, it pulls water along, reducing plasma volume. Systolic blood pressure drops by approximately 4-5 mmHg on average, a side effect that can be beneficial in hypertensive patients but dangerous in those who are already volume-depleted 5. Symptoms of volume depletion (dizziness, orthostatic hypotension, dehydration) occurred in 1.4% of empagliflozin-treated patients vs 0.8% on placebo in pooled analyses.

The FDA label for Jardiance specifically warns against initiation in patients with an eGFR below 20 mL/min/1.73 m² and recommends assessing volume status before starting the drug 9. Older adults on loop diuretics face the highest risk.

Tresiba has no diuretic properties. It does not affect blood pressure through any direct mechanism. In the context of a patient who is dehydrated, post-surgical, or on multiple antihypertensives, Tresiba is the safer choice from a volume standpoint.

Diabetic Ketoacidosis Risk

Euglycemic diabetic ketoacidosis (euDKA) is a rare but serious class effect of SGLT2 inhibitors. Because empagliflozin lowers glucose through a non-insulin pathway and promotes mild ketogenesis, patients can develop DKA with blood glucose levels that appear deceptively normal (under 250 mg/dL) 10.

The incidence is low in type 2 diabetes, approximately 0.1% or less per year in clinical trials. Risk factors include prolonged fasting, acute illness, surgery, very low carbohydrate diets, and latent autoimmune diabetes. The FDA issued a safety communication in 2015 advising temporary discontinuation of SGLT2 inhibitors before scheduled surgery 10.

Tresiba, as an insulin, actively prevents ketoacidosis. Basal insulin provides continuous suppression of lipolysis and ketogenesis. In a patient with a history of DKA episodes or borderline insulin deficiency, Tresiba is the pharmacologically safer option.

Renal Effects

Jardiance has shown renal protective effects that extend beyond glucose lowering. In the EMPA-KIDNEY trial (N=6,609), empagliflozin reduced the risk of kidney disease progression or cardiovascular death by 28% (HR 0.72 to 95% CI 0.64-0.82, P<0.001) in patients with chronic kidney disease, including those without diabetes 11. The mechanism involves reduced intraglomerular pressure through tubuloglomerular feedback.

A transient dip in eGFR (3-5 mL/min) during the first 4 weeks of treatment is expected and should not prompt discontinuation. This initial decrease reflects hemodynamic changes, not structural kidney damage, and is similar to the pattern seen with ACE inhibitors 11.

Tresiba has no direct nephroprotective or nephrotoxic effects. Its dosing does not require adjustment for renal impairment, though insulin clearance slows in advanced CKD, raising hypoglycemia risk. In clinical practice, insulin doses are often reduced by 25-50% when eGFR falls below 30 mL/min.

Less Common Side Effects

Jardiance

Fournier gangrene (necrotizing fasciitis of the perineum) has been reported across the SGLT2 inhibitor class. The FDA identified 55 cases over 5 years across all SGLT2 inhibitors, making this exceedingly rare but serious enough to earn a labeled warning 12. Lower limb amputation signals, which were prominent in the canagliflozin CANVAS trial, have not been replicated with empagliflozin at statistically significant rates.

Tresiba

Injection-site reactions are mild and uncommon (<2% of patients), but lipodystrophy can develop with repeated injection into the same area over months or years. Lipohypertrophy distorts insulin absorption, causing erratic glucose control. Peripheral edema occurs in a small fraction of patients initiating insulin therapy, typically self-limiting.

Allergic reactions to insulin degludec are rare. The FlexTouch pen device has a lower injection force than many comparators, which may improve adherence in needle-averse patients but has no bearing on the pharmacological side-effect profile.

Head-to-Head Summary Table

No randomized controlled trial has directly compared empagliflozin with insulin degludec. The following synthesis draws on EMPA-REG OUTCOME, DEVOTE, EMPA-KIDNEY, and pooled phase III program data for each drug.

| Side Effect | Jardiance (empagliflozin) | Tresiba (insulin degludec) | |---|---|---| | Hypoglycemia (monotherapy) | Rare (<1%) | Common (dose-dependent) | | Genital mycotic infections | 3-6% (women), 1-3% (men) | No increased risk | | Urinary tract infections | Modestly increased | No increased risk | | Weight change | -2 kg average | +1 to 3 kg average | | Volume depletion | 1.4% | Not applicable | | Blood pressure reduction | -4 to 5 mmHg systolic | None | | Euglycemic DKA | Rare (<0.1%) | Protective against DKA | | CV death reduction | 38% (EMPA-REG) | Neutral (DEVOTE) | | Renal protection | 28% risk reduction (EMPA-KIDNEY) | None demonstrated | | Injection-site reactions | None (oral) | <2% |

Dr. John Buse, former ADA President, has stated regarding second-line therapy selection: "The choice between an SGLT2 inhibitor and insulin should be guided by the patient's comorbid conditions, hypoglycemia risk, and weight management goals rather than HbA1c alone" 6.

When Each Drug Makes More Clinical Sense

Jardiance is the stronger choice for patients with established cardiovascular disease, heart failure with reduced ejection fraction, or chronic kidney disease with albuminuria, based on outcomes data from EMPA-REG OUTCOME and EMPA-KIDNEY. It also suits patients who cannot tolerate weight gain or who are at low risk for genital infections.

Tresiba is the better option when rapid HbA1c reduction is needed (it can lower HbA1c by 1.5-2.0% depending on the starting level and dose), when the patient has recurrent genital candidiasis, or when a patient has already experienced volume depletion events on a diuretic-heavy regimen. Patients with an eGFR below 20 mL/min cannot use Jardiance at all, making Tresiba the default in advanced CKD requiring glycemic control.

Many patients end up on both drugs simultaneously. In a 2019 real-world analysis of U.S. claims data, approximately 18% of patients prescribed an SGLT2 inhibitor were also receiving basal insulin 13. The side-effect profiles are largely complementary: Jardiance's weight loss partially offsets insulin-associated weight gain, and Tresiba's ketoacidosis-protective effect mitigates the euDKA risk of SGLT2 inhibitors.

The starting dose of Jardiance is 10 mg once daily, titrated to 25 mg if tolerated. Tresiba starts at 10 units once daily in insulin-naive patients, titrated by 2-4 units every 3-4 days to a fasting glucose target of 80-130 mg/dL per ADA guidelines 6.